Joseph Shan

489 total citations
24 papers, 401 citations indexed

About

Joseph Shan is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Joseph Shan has authored 24 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 9 papers in Oncology and 8 papers in Genetics. Recurrent topics in Joseph Shan's work include Phagocytosis and Immune Regulation (13 papers), Immune cells in cancer (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Joseph Shan is often cited by papers focused on Phagocytosis and Immune Regulation (13 papers), Immune cells in cancer (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Joseph Shan collaborates with scholars based in United States, India and Ukraine. Joseph Shan's co-authors include Susan P. Carpenter, William R. Shapiro, Barry W. Wessels, Sunil J. Patel, Anthony L. Asher, Randy L. Jensen, Douglas W. Laske, David E. Gerber, Alison Stopeck and Karen Roberts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Joseph Shan

23 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph Shan United States	10	137	113	104	103	83	24	401
Steven Park United States	14	132 1.0×	121 1.1×	132 1.3×	55 0.5×	282 3.4×	29	518
Matthew K. Schoen United States	7	363 2.6×	138 1.2×	105 1.0×	30 0.3×	127 1.5×	12	538
Larissa Sandalic United States	9	33 0.2×	111 1.0×	122 1.2×	43 0.4×	167 2.0×	13	403
Edward F. Schnipper United States	6	208 1.5×	206 1.8×	64 0.6×	30 0.3×	133 1.6×	6	492
Y. Piao United States	6	49 0.4×	261 2.3×	259 2.5×	69 0.7×	125 1.5×	10	541
Brigitte Collet France	9	211 1.5×	83 0.7×	162 1.6×	56 0.5×	183 2.2×	27	426
Russell Maxwell United States	11	191 1.4×	187 1.7×	81 0.8×	39 0.4×	259 3.1×	32	496
Adrian Kinzel United States	9	40 0.3×	192 1.7×	95 0.9×	28 0.3×	71 0.9×	35	401
Kok‐Siong Chen United States	12	85 0.6×	63 0.6×	211 2.0×	14 0.1×	109 1.3×	21	398
Nuray Gül Netherlands	7	350 2.6×	38 0.3×	142 1.4×	115 1.1×	178 2.1×	7	493

Countries citing papers authored by Joseph Shan

Since Specialization

Citations

This map shows the geographic impact of Joseph Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Shan more than expected).

Fields of papers citing papers by Joseph Shan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Shan. The network helps show where Joseph Shan may publish in the future.

Co-authorship network of co-authors of Joseph Shan

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Shan. A scholar is included among the top collaborators of Joseph Shan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Shan. Joseph Shan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vasu, Sumithira, Nelli Bejanyan, Steven M. Devine, et al.. (2020). BMT CTN 1803: Trial to Investigate If Haploidentical Natural Killer Cells (CSTD002) Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). Biology of Blood and Marrow Transplantation. 26(3). S371–S372. 1 indexed citations

Grilley‐Olson, Juneko E., Jared Weiss, Anastasia Ivanova, et al.. (2018). Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 19(4). e481–e487. 11 indexed citations

Mediavilla-Varela, Melanie, Jenny Kreahling, Bruce Freimark, et al.. (2017). Effect of bavituximab in combination with nivolumab on tumor immune response in a 3D ex vivo system of lung cancer patients.. Journal of Clinical Oncology. 35(15_suppl). e23091–e23091. 1 indexed citations

Kallinteris, Nikoletta L., Leora Horn, Min Tang, et al.. (2017). Abstract CT159: IFN-γ analysis in blood and tissue as a potential prognostic and/or predictive biomarker. Cancer Research. 77(13_Supplement). CT159–CT159. 2 indexed citations

Gerber, David E., David R. Spigel, Mikhail Shtivelband, et al.. (2016). Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 17(3). 169–176. 16 indexed citations

Natale, Ronald B., David R. Spigel, Rachel E. Sanborn, et al.. (2016). PPHM 1501- An open-label, randomized, phase II trial of durvalumab (MEDI4736) with or without bavituximab in patients with previously treated metastatic non-small cell lung cancer (NSCLC): Safety report on first 18 patients.. Journal of Clinical Oncology. 34(15_suppl). e14537–e14537. 1 indexed citations

Chalasani, Pavani, Marilyn Marron, Denise J. Roe, et al.. (2015). A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Medicine. 4(7). 1051–1059. 37 indexed citations

Yopp, Adam C., Amit G. Singal, Yull Arriaga, et al.. (2015). A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 33(15_suppl). 4109–4109. 1 indexed citations

Altiok, Soner, Jenny Kreahling, David Noyes, et al.. (2015). Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients.. Journal of Clinical Oncology. 33(15_suppl). 3060–3060. 1 indexed citations

10.

Altiok, Soner, Jenny Kreahling, David Noyes, et al.. (2015). Abstract 274: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer. Cancer Research. 75(15_Supplement). 274–274. 2 indexed citations

11.

Digumarti, Raghunadharao, P. P. Bapsy, G.S. Bhattacharyya, et al.. (2014). Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 86(2). 231–236. 34 indexed citations

12.

Gerber, David E., Joseph Shan, Ulrich Keilholz, et al.. (2014). Stimulating an immune response through bavituximab in a phase III lung cancer study.. Journal of Clinical Oncology. 32(15_suppl). TPS8129–TPS8129.

13.

Grilley‐Olson, Juneko E., Thomas E. Stinchcombe, Jared Weiss, et al.. (2013). Abstract B295: A Phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy-naïve incurable stage IIIb/IV non-squamous non-small cell lung cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). B295–B295. 1 indexed citations

14.

Shtivelband, Mikhail, David R. Spigel, David E. Gerber, et al.. (2013). Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.. Journal of Clinical Oncology. 31(15_suppl). 8095–8095. 10 indexed citations

15.

Pandya, Shuchi S., Lucas Wong, Andrea J. Bullock, et al.. (2013). Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma.. Journal of Clinical Oncology. 31(15_suppl). 4054–4054. 7 indexed citations

16.

Gerber, David E., Alison Stopeck, Lucas Wong, et al.. (2011). Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(21). 6888–6896. 56 indexed citations

17.

Jensen, Randy L., et al.. (2010). Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis. Current Cancer Therapy Reviews. 6(1). 13–18. 2 indexed citations

18.

Ibrahim, Nuhad K., Lucas Wong, Alison Stopeck, et al.. (2010). Abstract 5337: Phase 1 study of bavituximab in advanced solid tumor malignancies: Final results. Cancer Research. 70(8_Supplement). 5337–5337. 2 indexed citations

19.

Goris, Michael L., George A. Fisher, Barry W. Wessels, et al.. (2006). Phase I Study of ¹³¹ I-Chimeric(ch) TNT-1/B Monoclonal Antibody for the Treatment of Advanced Colon Cancer. Cancer Biotherapy and Radiopharmaceuticals. 21(3). 243–256. 27 indexed citations

20.

Shapiro, William R., Susan P. Carpenter, Karen Roberts, & Joseph Shan. (2006). ¹³¹I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opinion on Biological Therapy. 6(5). 539–545. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact